Flow cytometry
Staining and washing were performed in round bottom polystyrene 5 mL tubes (Falcon, 14–959-6). Unless otherwise stated, intracellular staining was performed with the BD biosciences Fixation/Permeabilization solution (BD Biosciences, 554,714) according to the manufacturer’s protocol. Beferdin A (BD Biosciences, 555,029) solution was used as the protein transport inhibitor during intracellular stainings. A 1:1000 dilution was incubated directly in cell culture plates for 4 h before stainings. Data were acquired using the Cytek Aurora (19-color panel) and the BD 5-laser LSR FORTESSA. Data were analyzed using FlowJo. V10 software.
Antibodies: Bone marrow HSCs: Anti-CD3-Biotin(Biolegend,1:400),TER119-Biotin(Biolegend,1:400),CD11b-Biotin (Biolegend,1:400), CD45R-Biotin(Biolegend,1:400), GR-1-Biotin (Biolegend,1:400), C-kit-APC (Biolegend,1:400), Sca-1-PECY7 (Biolegend,1:400), CD48-BV605 (Biolegend,1:300), CD150-BV450 (Biolegend,1:300), FLT3-PE (Biolegend,1:300), CD34-FITC (Biolegend,1:300), D16/32-APCCY7 (Biolegend, 1:300), IL7RA-BV785 (Biolegend,1:300). Spleens: CD19-AF647 (Biolegend, 1:1600), B220-AF700 (Biolegend, 1:800), IgM -BV605 (Biolegend, 1:200), IgD-PerCPCy5.5 (Biolegend, 1:400), CD3-APC/Fire810 (Biolegend, 1:150), CD4-PE/Dazzle 594 (Biolegend, 1:800), CD8-Pacific Blue (Biolegend, 1:600), CD44-BV421 (Biolegend, 1:400), CD62L-BV786 (BD, 1:1200), NK1.1-FITC(Biolegend, 1:300), TCRb-APC (Biolegend, 1:200), Ter119-BV650(Biolegend, 1:400), CD71-PE(Biolegend, 1:800), Ly6G-PE/Cy7 (Biolegend, 1:400), Ly6C-APC/Cy7(Biolegend, 1:400), CD11b-SparkYG593 (Biolegend, 1:800), CD11c-BV510(Biolegend, 1:150), F4/80-PE/Cy5 (Biolegend, 1:600), MHCII Spark Blue 550(Biolegend, 1:800), F4/80-PECY5 (Biolegend, 1:600), CD11c -PE (Biolegend, 1:600), GR1 (bv650) biotin (Biolegend, 1:500), CD126-PECY7(Biolegend, 1:400), CD86 (BV786)(Biolegend, 1:300), PD-L1-APC(Biolegend,1:1:200),CD44-PECY7 (Biolegend, 1:1:300),MHC1-PERCPCY5.5(Biolegend,1:1:200), CCR7-BV421 (Biolegend, 1:1:300),CD11b-FITC (Biolegend, 1:500), IL4-Rα-PECY7 (Biolegend, 1:300),IL-6-PE(Biolegend, 1:100), IRF4-BV421 (Biolegend, 1:100), iNOS-APC (Biolegend, 1:300).
Generation of BMDMs and BMDCs
Bone marrow from both femurs and tibiae was harvested in Dulbecco's High Glucose Modified Eagles Medium (DMEM) (Cytiva, SH30022FS) supplemented with 10% heat-inactivated FBS (Life technologies, 12,483,020). Marrows were filtered through a 70 μm Nylon cell strainer (Corning, 07–201-431) to remove solid fragments. The filtrate was centrifuged at 300 × g for 5 min at 4 °C. Cells were subsequently seeded in 2 ml DMEM supplemented with 10% hi-FBS, 1% non-essential amino acids (Gibco, 11,140,050), 1 mM sodium pyruvate (Gibco, 11,360,070), 2 mM L-Glutamine (Glutamax) (Gibco, 35,050,061), 100U/ml penicillin–streptomycin (Gibco, 15,140,122) in 6-well plates at a density of 1 × 105 cells/mL. Recombinant murine M-CSF (Preprotech, 315–02) was added directly to the wells on days 0, 3, and 6 at a final concentration of 30 ng/mL. The same method was employed to generate BMDCs, but with 20 ng/mL of recombinant murine GM-CSF (Preprotech, 315–03) and 5 ng/mL of recombinant murine IL-4 (Preprotech, 214–14). BMDCs were in their immature “unactivated” state during that study. Cells were harvested by gentle scraping and washing with PBS. Washed cells were then used for downstream applications.
For the polarization, 100 ng/mL of LPS (LPS from E. coli O111:B4, InVivogen, tlrl-3pelps) and 20 ng/mL of recombinant murine IFNγ (Preprotech, 315–05) were used to induce M1 macrophages for 24 h. For M2 macrophages, 20 ng/mL of recombinant murine IL-4 (Preprotech, 214–14) was added to the culture wells for 24 h.
The TAO kinases inhibitor, compound 43, was diluted in DMSO (water insoluble) and purchased from Cayman chemicals (Ref: 25632).
Enzyme-linked immunosorbent assays (ELISA) and cytokine/chemokine multiplexing
Supernatant from BMDM cultures was collected on day 7 ( 24 h post-polarization) and kept at -80C until downstream analysis. Mouse IL-6 (Biolegend, 431,301) and TNFα (Biolegend, 430,904) were used as per the manufacturer's protocol.
For cytokine multiplexing, serum was collected through cardiac puncture using 1 mL syringes and 25G × 1 needles (BD biosciences). Blood was transferred to S-Monovette® Serum Gel, 1.1 mL collection vessels (Sarstedt, 06.1667.001) and was left to cloth for 30 min at room temperature. Vessels were then centrifuged at 2000 × g for 10 min. Supernatants (serum) were collected and stored in new tubes at -80C until downstream analysis. For cytokine multiplexing, serum was diluted onefold before being sent to EVE Technologies, Calgary, Alberta, Canada, for cytokine multiplexing with a Bio-Plex 200.